

# Synergism of cationic antimicrobial peptide WLBU2 with antibacterial agents against biofilms of multi-drug resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae*

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

Samer Swedan <sup>1</sup>

Zaina Shubair <sup>1</sup>

Ammar Almaaytah <sup>2</sup>

<sup>1</sup>Jordan University of Science and Technology, Department of Medical Laboratory Sciences, Irbid, Jordan;

<sup>2</sup>Jordan University of Science and Technology, Department of Pharmaceutical Technology, Irbid, Jordan

**Purpose:** The activity of the cationic antimicrobial peptide WLBU2 was evaluated against planktonic cells and biofilms of multi-drug resistant (MDR) *Acinetobacter baumannii* and *Klebsiella pneumoniae*, alone and in combination with classical antimicrobial agents.

**Methods:** Control American Type Culture Collection (ATCC) strains and MDR clinical isolates of *A. baumannii* and *K. pneumoniae* were utilized. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of WLBU2 alone and in combination with antimicrobials were determined by classical methods. The Calgary biofilm device was used to determine the minimum biofilm eradication concentration (MBEC). The MTT assay was used to determine the cytotoxicity of agents on eukaryotic cells. The electrophoretic mobility shift assay was used to evaluate the ability of WLBU2 to bind bacterial DNA.

**Results:** The WLBU2 MIC and MBC values were identical indicating bactericidal activity. The MIC/MBC values ranged from 1.5625 to 12.5  $\mu$ M. At these concentrations, Vero cells and human skin fibroblasts were viable. The MBEC of WLBU2 ranged from 25 to 200  $\mu$ M. A significant loss of eukaryotic cell viability was observed at the MBEC range. The combination of sub-inhibitory concentrations of WLBU2 with amoxicillin-clavulanate or ciprofloxacin for *K. pneumoniae*, and with tobramycin or imipenem for *A. baumannii*, demonstrated synergism, leading to a significant decrease in MIC and MBEC values for some isolates and ATCC strains. However, all combinations were associated with considerable loss in eukaryotic cells' viability. WLBU2 did not demonstrate the ability to bind bacterial plasmid DNA.

**Conclusion:** WLBU2 in combination with antimicrobials holds promise in eradication of MDR pathogens.

**Keywords:** antimicrobial peptide, synergy, combination therapy, biofilm, multi-drug resistance, bacteria

## Introduction

Bacterial resistance to conventional antimicrobials is increasing year after year and is a global health emergency.<sup>1</sup> Biofilm formation is a common mechanism to overcome the activity of antimicrobials and the host immune response. Due to treatment difficulties, biofilm-associated infections have led to significant rates of morbidity and mortality among the community and the health-care settings.<sup>2,3</sup> Hence,

Correspondence: Samer Swedan  
Jordan University of Science and Technology, Department of Medical Laboratory Sciences, PO Box 3030, Irbid 22110, Jordan  
Tel +962 2 720 1000 ext. 26886  
Fax +962 2 720 1087  
Email sfswedan4@just.edu.jo

developing safe alternate therapies with diverse mechanisms of action research is urgently needed.<sup>4–6</sup>

Antimicrobial peptides (AMPs) are immune effector molecules that are being considered as potential alternatives for conventional antimicrobial agents. AMPs demonstrate multiple mechanisms of action, including formation of trans-membrane pores, which lead to lysis of microorganisms, the deterioration of bacterial viability by interfering with cell wall biosynthesis,<sup>7,8</sup> the disruption of biochemical processes, and enhancement and activation of the immune response. Some AMPs are effective against biofilm and multi-drug resistant (MDR) bacteria, with rapid killing kinetics.<sup>9</sup> Hence, AMPs have advantages over antimicrobial agents, as the bacteria are less likely to produce and transfer resistance genes against the peptides.<sup>7</sup>

Most AMPs are cationic peptides with an amphipathic structure that selectively targets bacterial membranes via electrostatic forces.<sup>10</sup> WLBU2 is a 24-residue engineered cationic amphipathic peptide (eCAP) that consists of only three types of amino acids: tryptophan, valine, and arginine. The WLBU2 sequence was rationally designed by amino acid substitutions from precursor peptides to have an ideal amphipathic helix conformation to maximize antimicrobial properties, while minimizing epithelial cell cytotoxicity.<sup>11–13</sup>

*Acinetobacter baumannii* is a significant Gram-negative MDR pathogen associated with urinary tract infections, pulmonary infections, wound infection, and infections of other tissues and organs. *A. baumannii* has the ability to form biofilms, leading to increased virulence.<sup>14,15</sup> *Klebsiella pneumoniae* is a Gram-negative, encapsulated, opportunistic pathogen associated with pneumonia, meningitis, urinary tract infections, sepsis,

and surgical wound site infections. *K. pneumoniae* is the main cause of health care-associated *Klebsiella* infections, mostly involving the respiratory and urinary tracts.<sup>16</sup>

This study provides insights on the activity of WLBU2 against planktonic and biofilm-producing MDR *A. baumannii* and *K. pneumoniae*, and in combination with classical antimicrobial agents. This study also examined the potential toxicity of WLBU2-antimicrobials combinations on human skin fibroblast cells and Vero cells, and the ability of WLBU2 to bind bacterial DNA. The findings pave the way for future investigations that can potentially culminate in the development of treatments for difficult to treat and biofilm-associated infections.

## Materials and methods

The study was approved by Jordan University of Science and Technology (JUST) research committee. Requirement for approval by the institutional review board of JUST was waived as the study did not involve the study of human subjects, human data or tissue, or animals.

## Bacterial strains

Forty-three *K. pneumoniae* (n=24) and *A. baumannii* (n=19) clinical isolates, which were previously isolated and stored at –80°C from four major hospitals in Jordan were utilized in this study. All isolates had an MDR phenotype (resistance to at least three antimicrobial agent classes; data not shown). Six *A. baumannii* and *K. pneumoniae* control strains obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) were also included (Table 1).

**Table 1** ATCC strains utilized in the study

| Species                        | ATCC number | Characteristics                                                                                                                                                       |
|--------------------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Acinetobacter baumannii</i> | BAA-1605    | Resistance to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem. Susceptible to amikacin and tobramycin |
|                                | 19606       | Quality control strain                                                                                                                                                |
| <i>Klebsiella pneumoniae</i>   | BAA-2146    | Quality control strain                                                                                                                                                |
|                                | BAA-1705    | Carbapenem-resistant (imipenem and ertapenem)                                                                                                                         |
|                                | BAA-1706    | Quality control strain                                                                                                                                                |
|                                | 700603      | Control for extended beta-lactamase production<br>Quality control strain.                                                                                             |

**Abbreviation:** ATCC, American Type Culture Collection.

## WLBUE2

WLBUE2 is a peptide consisting of 24-amino acid residues. The amino acid sequence is (RRWVRRVRRWVRRV RVVRRWVRR). The molecular weight is 3398 g/mol (~3400 g/mol). WLBUE2 was synthesized by GL Biochem (Minhang Qu, Shanghai Shi, People's Republic of China). Synthesis was based on the solid phase method and standard Fmoc chemistry. The confirmation and purification of the synthesized peptide was performed by mass spectrometry and HPLC. The purity was 95.71%. WLBUE2 concentration conversion from  $\mu\text{M}$  to  $\mu\text{g/mL}$  can be done by multiplying the value in  $\mu\text{M}$  by (3.4).

## Antimicrobial agents

Four antimicrobials (Cayman Chemicals, Ann Arbor, MI, USA) were used for susceptibility tests. Imipenem and tobramycin were utilized for *A. baumannii* experiments, while amoxicillin/clavulanate and ciprofloxacin were utilized for *K. pneumoniae* experiments. The antimicrobial agent choices were based on the recommendations by the Clinical and Laboratories Standards Institute (CLSI) antimicrobial susceptibility testing standards, 26th edition (2016).

## Cell lines

Eukaryotic cell viability experiments utilized Vero cells (African green monkey kidney epithelial cells; ATCC CCL-81) and human skin fibroblast cells (ATCC PCS-201-012). Both cell lines were obtained from the ATCC.

## Quantitative biofilm formation assay

The 96-well tissue culture plate method was utilized for quantitative evaluation of biofilm formation as described previously with modifications.<sup>17</sup> Briefly, the clinical isolates and ATCC strains were subcultured from frozen glycerol stock onto nutrient agar to obtain pure-well isolated colonies. Next, two to three colonies were inoculated in 10 mL of trypticase soy broth with 1% glucose. The broth cultures were incubated at 37°C for 24 hrs and were diluted 1:100 with fresh medium. Individual wells of a sterile 96-well plate were filled with 200  $\mu\text{L}$  of the diluted cultures. Negative control wells contained sterile broth media. The microtiter plate was incubated for 24 hrs at 37°C. The contents of each well were discarded by inversion and gentle tapping on absorbent paper towels, and the wells were washed with 200  $\mu\text{L}$  of PBS (pH 7.2) three to four times to remove free-floating planktonic

bacteria. Next, 200  $\mu\text{L}$  of 0.1% crystal violet solution in water were added per well for 30 mins at room temperature to stain the biofilms. The plate was rinsed with deionized water to remove excess stain. Finally, 200  $\mu\text{L}$  of absolute ethanol were added to each well to solubilize the stain. Absorbance at 575 nm ( $\text{OD}_{575}$ ) was measured for each well to obtain quantitative data on biofilm formation, using an Epoch ELISA plate reader (BioTek, Winooski, VT, USA).

The test was carried out in duplicates and the average was calculated for each bacterial strain. The cutoff optical density ( $\text{OD}_c$ ) for biofilm formation was defined as three standard deviations above the mean OD of the negative control. Optical density data were interpreted according to Table 2.

## Minimum inhibitory and bactericidal concentrations of WLBUE2 against planktonic bacteria

To determine the lowest concentration of WLBUE2 required to inhibit visible growth of the microorganisms, WLBUE2 was dissolved in PBS (pH=7.3) to achieve 100  $\mu\text{M}$  or 340  $\mu\text{g/mL}$ . The peptide was serially diluted twofold from 100 to 1.563  $\mu\text{M}$  or 340 to 5.313  $\mu\text{g/mL}$ . The clinical isolates and ATCC strains were cultured in sterile Muller-Hinton broth (MHB) (Oxoid, Basingstoke, Hampshire, UK), incubated aerobically overnight, and diluted with fresh MHB media to reach  $10^6$  CFU/mL. Next, 50  $\mu\text{L}$  of the respective peptide concentrations and 50  $\mu\text{L}$  of bacterial suspension were added to wells of sterile 96-well polypropylene microtiter plates. Plates were incubated at 37°C for 20 hrs in a humidified incubator. The minimum inhibitory concentration (MIC) of the peptide capable of inhibiting visible bacterial growth was quantitatively determined by measuring  $\text{OD}_{600}$  for each well using an Epoch ELISA plate reader (BioTek). All MIC determinations were made in triplicate. Sterile MHB (Oxoid)

**Table 2** Interpretation of optical density data for detection of biofilm formation

| Average OD value                                             | Interpretation             |
|--------------------------------------------------------------|----------------------------|
| $\text{OD} \leq \text{OD}_c$                                 | No biofilm formation       |
| $\text{OD}_c < \text{OD} \leq 2 \times \text{OD}_c$          | Weak biofilm formation     |
| $2 \times \text{OD}_c < \text{OD} \leq 4 \times \text{OD}_c$ | Moderate biofilm formation |
| $4 \times \text{OD}_c < \text{OD}$                           | Strong biofilm formation   |

**Notes:** All OD values were measured at 575 nm;  $\text{OD}_c$ , average OD of negative control +3x standard deviation of the negative controls.<sup>18</sup>

**Abbreviation:**  $\text{OD}_c$ , optical density cutoff value.

was used as negative control. Wells having bacteria alone without the peptide served as positive controls.<sup>19</sup>

The minimum bactericidal concentration (MBC) of WLBU2 needed to kill  $\geq 99.9\%$  of bacteria was determined by inoculating 10  $\mu\text{L}$  from the wells demonstrating the MIC concentration or higher, on Muller-Hinton agar (Oxoid) (incubated for 24 hrs at 37°C) to count viable cells. The lowest concentration that led to  $\geq 99.9\%$  decrease in CFUs/mL was considered the MBC.

## MIC of antimicrobial agents

The minimum concentration capable of inhibiting visible bacterial growth was determined for each antimicrobial agent. A specific weigh for each antimicrobial agent was dissolved in PBS (pH =7.3) to yield stock concentrations. The stock concentrations corresponded to the upper limits of MIC values as indicated by CLSI antimicrobial susceptibility testing guidelines (2016). Bacterial density was fixed to approximately  $10^6$  CFU/mL. Next, 50  $\mu\text{L}$  of the bacteria were added to wells having 50  $\mu\text{L}$  of each antimicrobial agent concentration (twofold serial dilution) in 96-well plates, and the plates were incubated aerobically overnight at 37°C. The MIC values were determined by measuring OD<sub>600</sub> using an Epoch ELISA plate reader (BioTek).

## Synergism between WLBU2 and antimicrobial agents against planktonic bacteria

Briefly, 25  $\mu\text{L}$  of the WLBU2 at its sub-MIC level for each respective isolate (ie, concentration=25% of MIC) was added to a 50  $\mu\text{L}$  inoculum of  $10^5$  CFU/mL planktonic bacteria, in respective wells of a 96 well microtiter plates, in triplicates. Next, serial dilutions of the antimicrobial agents at 25  $\mu\text{L}$  volumes were added to the wells, and the plates were incubated at 37°C for 24 hrs. Absorbance was measured as an indicator of growth inhibition (OD<sub>600</sub>) using an Epoch ELISA plate reader (BioTek).<sup>20</sup> The CLSI, 2016 concentration values for resistance, intermediate susceptibility, and susceptibility, respectively, in  $\mu\text{g/mL}$  were 128, 64, and 32 for amoxicillin-clavulanate, 16, 8, and 4 for ciprofloxacin, 64, 32, and 16 for tobramycin, and 32, 16, and 8 for imipenem.

## Minimum biofilm eradication concentration (MBEC) of WLBU2 against biofilm-forming bacteria

The Calgary biofilm device (Innovotech, Edmonton, Alberta, Canada) method is a reliable assay of biofilm

formation. In this study, the Calgary biofilm device was used to determine WLBU2's MBEC against ATCC strains and several representative biofilm-forming clinical isolates. Briefly, 150  $\mu\text{L}$  of bacterial suspensions having a density of  $10^5$  CFU/mL were transferred into wells of a 96-well MBEC plate. Next, the plate's lid having the pegs was placed, and the plate was put on a platform shaker incubator set at 110 rpm and 37°C for 20 hrs, to allow for biofilm formation on lid pegs. Negative control wells had 150  $\mu\text{L}$  of sterile MHB (Oxoid, ). Following incubation, the lid pegs were washed three times with sterile PBS to remove non-adherent cells.

Next, a challenge plate was prepared by transferring 200  $\mu\text{L}$  of each WLBU2 concentration (twofold serial dilutions made in PBS) to respective wells of the plate. Next, lid pegs were placed, and the plate was incubated at 37°C for 18 hrs. The lid pegs were subsequently placed into a recovery plate, containing fresh MHB (Oxoid) and the plate was sonicated for 30 mins in a water bath. Finally, the plate was incubated with the lid pegs at 37°C for 20 hrs. To determine MBEC values, growth in each well was determined by measuring OD<sub>600</sub> using an Epoch ELISA plate reader (BioTek). The MBEC value for each strain corresponded with the lowest WLBU2 concentration resulting in growth inhibition. All samples were run in triplicates.

## Antimicrobial agents' MBEC in the presence of WLBU2 at sub-MBEC

The experiment was performed as described for the MBEC assay above with the following changes: the challenge plate was prepared by adding 25  $\mu\text{L}$  of WLBU2 at its sub-MBEC level for each respective isolate (ie, concentration=25% of MBEC) in respective wells of 96-well microtiter plates. Next, 25  $\mu\text{L}$  of serial dilutions of the antimicrobial agents were added, and the plates were incubated at 37°C for 24 hrs. The MBEC values for the antimicrobial agents corresponded with the lowest concentration that resulted in growth inhibition. All samples were run in triplicates.

## Cell viability assay

The MTT assay was used to assess potential reduction in cell viability after treatment of eukaryotic cells with WLBU2 alone and in combination with antimicrobial agents. Briefly, Vero cells and human skin fibroblasts were seeded in a flat-bottomed 96-well plate at 5000 cells (in 100  $\mu\text{L}$ ) per well, and incubated at 37°C for 24

hrs under 5% CO<sub>2</sub>. Next, medium was removed, and 100 µL of fresh media containing different concentrations of the WLBU2 alone or in combination with the antimicrobial agents at the indicated CLSI resistance cutoff values were added per respective wells. The plates were incubated at 37°C for 24 hrs, and medium was replaced with fresh medium containing 30 µL (2.5 mg/mL) MTT solution (Sigma-Aldrich, St. Louis, MO, USA). The plate was incubated for 4–6 hrs at 37°C, under 5% CO<sub>2</sub>. After medium/MTT was removed, 100 µL DMSO were added to dissolve the formazan crystals. Cell survival rates were calculated by measuring absorbance at 540 nm using an Epoch ELISA plate reader (BioTek). Medium without treatment was used for the positive control wells. All tests were run in triplicates.

The true relative value of viable cells was calculated using the equation: (Sample A<sub>570</sub>-Background A<sub>650</sub>)/(Control A<sub>570</sub>-Background A<sub>650</sub>)×100.

## DNA binding assay

The ability of the WLBU2 to bind bacterial plasmid DNA was investigated using the electrophoretic mobility shift assay. In brief, various concentrations of WLBU2 (range: 200–1.563 µM or 680–5.313 µg/mL) were incubated with 250 ng of bacterial plasmid DNA (pUC19; 2686 base pairs, NEB, USA) in 30 µL binding buffer (10 mM Tris-HCl and 1 mM EDTA buffer, pH 8.0) at room temperature for 30 mins. After incubation, 20 µL of the mixture were analyzed by electrophoretic separation on 1.5% agarose gel. Each gel also included 7 µL of 1 Kb DNA ladder (NEB, USA) per well. DNA migration was visualized by ethidium bromide staining followed by UV transillumination.<sup>4</sup>

## Data analysis

Data analysis was performed using Microsoft Excel version 2016 (Microsoft, Redmond, Washington, USA) and GraphPad

Prism version 6.05 (GraphPad Software, San Diego, CA, USA). All values represent means of multiple runs.

## Results

### Quantitative biofilm detection using 96-well plate assay

Four *K. pneumoniae* clinical isolates (ID# 6, 12, 18, and 20) were moderate biofilm producers, while the remaining 20 isolates and all 19 *A. baumannii* clinical isolates were strong biofilm producers. *K. pneumoniae* ATCC strains (BAA-2146, BAA-1706 and 700603) were strong biofilm producers, while BAA-1705 showed moderated biofilm production. *A. baumannii* ATCC strains 19606 showed moderate biofilm production, while BAA-1605 showed strong biofilm production.

### MIC and MBC for WLBU2 against planktonic bacteria

MIC and MBC values were identical for each respective isolate and control strain (Table 3). MIC/MBC values for WLBU2 ranged from 3.125 to 12.500 µM or 10.625 to 42.500 µg/mL for *K. pneumoniae* clinical isolates (mean=7.943 µM or 27.006 µg/mL), and 1.563 to 12.500 µM or 5.313 to 42.500 µg/mL for *A. baumannii* clinical isolates (mean=7.484 µM or 25.446 µg/mL).

### MIC of antimicrobial agents

Table 4 summarizes the MIC values of the study isolates and control strains against antimicrobial agents.

### Synergistic activity of WLBU2 at 25% MIC with antimicrobial agents against planktonic bacteria

Bacterial isolates that demonstrated intermediately susceptible or resistant MIC values against antimicrobial agents

**Table 3** MIC and MBC results of WLBU2 against study isolates

| <i>K. pneumoniae</i> ID#                    | <i>A. baumannii</i> ID#            | MIC/MBC value (µM; [µg/mL]) |
|---------------------------------------------|------------------------------------|-----------------------------|
| –                                           | 36                                 | 1.563 [5.313]               |
| 2, 4, 8, 16, 23                             | 32, 38, 41                         | 3.125 [10.625]              |
| ATCC BAA-2146, ATCC BAA-1705, ATCC BAA-1706 | ATCC BAA-1605                      |                             |
|                                             | ATCC 19606                         |                             |
| 1, 5–7, 10, 12, 17, 18, 20, 21              | 26, 28, 29, 31, 34, 35, 37, 39, 42 | 6.250 [21.250]              |
| ATCC 700603                                 |                                    |                             |
| 3, 9, 11, 13–15, 19, 22, 24                 | 25, 27, 30, 33, 40, 43             | 12.500 [42.500]             |

**Note:** MICs indicated represent values for each respective clinical isolate or control strain.

**Abbreviations:** ID#, identification number; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration.



**Table 4** Study isolates' MIC values against antimicrobial agents

| Species              | Antimicrobial agent     | Isolate ID# (MIC value)   |                              |                                                                |
|----------------------|-------------------------|---------------------------|------------------------------|----------------------------------------------------------------|
|                      |                         | Susceptible               | Intermediate                 | Resistant                                                      |
| <i>K. pneumoniae</i> | Amoxicillin-clavulanate | –                         | –                            | 8, 12, ATCC 700603 (32 µg/mL)                                  |
|                      |                         |                           |                              | 1–7, 9–11, 13–24 (>32 µg/mL)                                   |
|                      | Ciprofloxacin           | 12, ATCC 700603 (1 µg/mL) | –                            | 7, ATCC BAA-1706 (8 µg/mL)                                     |
|                      |                         |                           |                              | 1–6, 8–11, 13–24 (>8 µg/mL)                                    |
| <i>A. baumannii</i>  | Tobramycin              | ATCC 19606 (4 µg/mL)      | ATCC BAA-1605 (MIC =8 µg/mL) | 36, 43 (16 µg/mL)                                              |
|                      |                         |                           |                              | 25–35, 37–42 (>16 µg/mL)                                       |
|                      | Imipenem                | ATCC 19606 (2 µg/mL)      | –                            | 26, 30, ATCC BAA-1605 (8 µg/mL)<br>25, 27–29, 31–43 (>8 µg/mL) |

**Note:** MICs indicated represent values for each respective clinical isolate or control strain.

**Abbreviations:** ID#, identification number; MIC, minimum inhibitory concentration.

were utilized for potential synergistic activity testing between WLBU2 at its sub-inhibitory concentration (25% of WLBU2 MIC for each respective isolate), with antimicrobial agents at different concentrations. Results are indicated in [Table 5](#).

Overall, synergism was observed for *K. pneumoniae* between WLBU2 and amoxicillin-clavulanate in two instances of six, and for ciprofloxacin in two instances of four. Synergism was observed for *A. baumannii* between WLBU2 and tobramycin in none of the three instances, and for imipenem in two instances of three.

## MBEC

MBEC testing was done for WLBU2 alone, followed by synergy testing between WLBU2 at 25% of MBEC values combined with antimicrobial agents at different concentrations. The tests were done for all ATCC strains and for representative clinical isolates that demonstrated synergism between WLBU2 (at sub-MIC values for planktonic cells) and the antimicrobial agents. Results are indicated in [Table 6](#).

The ability of WLBU2 alone to eradicate biofilms was assessed against *K. pneumoniae* clinical isolates 7 and 12, and *A. baumannii* clinical isolate 30. The measured MBEC values were 100 µM (340 µg/mL), 50 µM (170 µg/mL), and 100 µM (340 µg/mL), respectively. MBEC values ranged from 25 to >200 µM or 85 to >680 µg/mL for *K. pneumoniae* ATCC strains and were 50 µM or 170 µg/mL, for each of the two *A. baumannii* ATCC strains ([Table 6](#)).

MBEC values were also determined for amoxicillin-clavulanate, ciprofloxacin, tobramycin, and imipenem,

when combined with WLBU2 (at 25% MBEC). WLBU2 demonstrated synergism against *K. pneumoniae* in four of four instances when combined with amoxicillin-clavulanate, and in three of four instances when combined with ciprofloxacin. WLBU2 demonstrated synergism against *A. baumannii* in two of two instances when combined with tobramycin, and in three of three instances when combined with imipenem.

## Cytotoxicity tests

Vero cells and human skin fibroblast were used in MTT assays for viability testing of WLBU2 alone (at 1.563–200 µM or 5.313–680 µg/mL) ([Figure 1](#)), and of WLBU2 at 25 µM (85 µg/mL) or 12.500 µM (42.5 µg/mL) combined with antimicrobial agents at different concentrations ([Figure 2](#)).

Vero cells and human skin fibroblasts were viable at WLBU2 concentrations ≤3.125 µM (10.625 µg/mL) and ≤12.500 µM (42 µg/mL), respectively ([Figure 1](#)). Both cell types showed markedly reduced cell viability when WLBU2 was tested in combination with antimicrobial agents at all tested concentrations ([Figure 2](#)).

## DNA binding assay

WLBU2 did not demonstrate DNA binding ability when tested with pUC19 plasmid DNA ([Figure 3](#)).

## Discussion

WLBU2 is one of the newly synthesized cAMPs, that displayed promising activity against Gram-positive and

**Table 5** Result of synergistic testing between sub-inhibitory WLBU2 concentrations and antimicrobial agents for planktonic cells

| Species              | Antimicrobial agent     | Isolate ID#   | MIC of anti-microbial agent alone (µg/mL) | Synergism test                                               |                                                               |                                     |
|----------------------|-------------------------|---------------|-------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------|
|                      |                         |               |                                           | Concentration of WLBU2 used for synergism test (µM; [µg/mL]) | Observed antimicrobial agent MIC (µg/mL) in presence of WLBU2 | Synergism observed (interpretation) |
| <i>K. pneumoniae</i> | Amoxicillin-clavulanate | 8             | 32                                        | 0.781 [2.655]                                                | >32                                                           | No                                  |
|                      |                         | 12            | 32                                        | 1.563 [5.314]                                                | 8                                                             | Yes (susceptible)                   |
|                      |                         | ATCC BAA-2146 | >32                                       | 0.781 [2.655]                                                | >32                                                           | No                                  |
|                      |                         | ATCC BAA-1705 | >32                                       | 0.781 [2.655]                                                | 16                                                            | Yes (intermediate)                  |
|                      |                         | ATCC BAA-1706 | >32                                       | 0.781 [2.655]                                                | >32                                                           | No                                  |
|                      |                         | ATCC 700603   | 32                                        | 1.563 [5.314]                                                | >32                                                           | No                                  |
|                      | Ciprofloxacin           | 7             | 8                                         | 1.563 [5.314]                                                | 2                                                             | Yes (intermediate)                  |
|                      |                         | BAA-2146      | >4                                        | 0.781 [2.655]                                                | >4                                                            | No                                  |
|                      |                         | BAA-1705      | >4                                        | 0.781 [2.655]                                                | >4                                                            | No                                  |
|                      |                         | BAA-1706      | 8                                         | 0.781 [2.655]                                                | 4                                                             | Yes (resistant)                     |
| <i>A. baumannii</i>  | Tobramycin              | 36            | 16                                        | 0.391 [1.329]                                                | >16                                                           | No                                  |
|                      |                         | 43            | 16                                        | 0.781 [2.655]                                                | >16                                                           | No                                  |
|                      |                         | ATCC BAA-1605 | 8                                         | 0.781 [2.655]                                                | >16                                                           | No                                  |
|                      | Imipenem                | 26            | 8                                         | 1.563 [5.314]                                                | 8                                                             | No                                  |
|                      |                         | 30            | 8                                         | 0.781 [2.655]                                                | 2                                                             | Yes (susceptible)                   |
|                      |                         | ATCC BAA-1605 | 8                                         | 0.781 [2.655]                                                | 4                                                             | Yes (intermediate)                  |

**Note:** Concentration of WLBU2 used for synergism test corresponded with 25% of MIC values for each respective clinical isolate or control strain.

**Abbreviations:** ID#, identification number; MIC, minimum inhibitory concentration.

Gram-negative bacterial pathogens, MDR pathogens, and bacterial biofilms.<sup>21,22</sup>

The current study utilized MDR clinical isolates of *A. baumannii* and *K. pneumoniae*. The clinical isolates were from a variety of sources, including the urinary tract, blood, synovial fluid, bronchial washings, sputum, and wound material (data not shown). Several ATCC strains were included as controls. The findings of this study may pave the way for alternate therapies for bacterial pathogens that are highly resistant to classical antimicrobial agents and that produce hard to treat biofilm-associated infections.

The clinical isolates and the ATCC strains were first tested for the ability to produce biofilms using the reliable 96-well tissue culture plate method using crystal violet staining. All *A. baumannii* and 88.33% of *K. pneumoniae* clinical isolates, and most ATCC strains demonstrated strong biofilm formation. Only 16.78% of *K. pneumoniae* clinical isolates and one ATCC strain from each species

demonstrated moderate biofilm production. Other methods for evaluation of biofilm formation include the Congo red agar (CRA) method. However, CRA is not a reliable biofilm assay, as it was reported to have little sensitivity, specificity, and accuracy.<sup>23,24</sup>

The MIC of WLBU2 was determined against planktonic *A. baumannii* and *K. pneumoniae* clinical isolates and the ATCC strains utilizing a concentration range of 100–1.563 µM or 340–5.313 µg/mL. This range was selected based on previous reports on WLBU2 that indicated MIC values well below 100 µM or 340 µg/mL.<sup>11,12</sup>

Mean MIC values for WLBU2 were 7.943 µM (27.006 µg/mL) and 7.484 µM (25.446 µg/mL) for *K. pneumoniae* and *A. baumannii* clinical isolates, respectively. Importantly, all individual MBC and MIC values were identical, indicating that WLBU2 is bactericidal. This is compatible with previous reports indicating that engineered cationic peptides (eCAPs) have fast killing activity

**Table 6** MBEC results of WLBU2 alone, and of antimicrobial agents in combination with sub-MBEC WLBU2 concentrations

| Species              | Antimicrobial agent     | Isolate ID#   | MBEC of WLBU2 alone ( $\mu\text{M}$ ; [ $\mu\text{g/mL}$ ]) | Synergism test                                                                         |                                                                             |                                     |
|----------------------|-------------------------|---------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------|
|                      |                         |               |                                                             | Concentration of WLBU2 used for synergism test ( $\mu\text{M}$ ; [ $\mu\text{g/mL}$ ]) | Observed antimicrobial agent MBEC ( $\mu\text{g/mL}$ ) in presence of WLBU2 | Synergism observed (interpretation) |
| <i>K. pneumoniae</i> | Amoxicillin-clavulanate | 12            | 100 [340]                                                   | 25 [85]                                                                                | 8                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC BAA-2146 | >200 [>680]                                                 | 50 [170]                                                                               | 8                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC BAA-1705 | 25 [85]                                                     | 8.125 [27.625]                                                                         | 8                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC BAA-1706 | 100 [340]                                                   | 25 [85]                                                                                | 8                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC 700603   | >200 [>680]                                                 | 50 [170]                                                                               | 8                                                                           | Yes (susceptible)                   |
|                      | Ciprofloxacin           | 7             | 50 [170]                                                    | 12.500 [42.500]                                                                        | 1                                                                           | Yes (susceptible)                   |
|                      |                         | BAA-2146      | >200 [>680]                                                 | 50 [170]                                                                               | 1                                                                           | Yes (susceptible)                   |
|                      |                         | BAA-1705      | 25 [85]                                                     | 8.125 [27.625]                                                                         | 4                                                                           | No                                  |
|                      |                         | BAA-1706      | 100 [340]                                                   | 25 [85]                                                                                | 1                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC 700603   | >200 [>680]                                                 | 50 [170]                                                                               | 1                                                                           | Yes (susceptible)                   |
| <i>A. baumannii</i>  | Tobramycin              | ATCC BAA-1605 | 50 [170]                                                    | 12.500 [42.500]                                                                        | 8                                                                           | Yes (intermediate)                  |
|                      |                         | ATCC 19606    | 50 [170]                                                    | 12.500 [42.500]                                                                        | 8                                                                           | Yes (intermediate)                  |
|                      | Imipenem                | 30            | 100 [340]                                                   | 25 [85]                                                                                | 2                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC BAA-1605 | 50 [170]                                                    | 12.500 [42.500]                                                                        | 2                                                                           | Yes (susceptible)                   |
|                      |                         | ATCC 19606    | 50 [170]                                                    | 12.500 [42.500]                                                                        | 2                                                                           | Yes (susceptible)                   |

**Note:** Concentration of WLBU2 used for synergism test corresponded with 25% of MBEC values for each respective clinical isolate or control strain.

**Abbreviations:** ID#, identification number; MBEC, minimum biofilm eradication concentration.

on bacterial cells<sup>25</sup> For comparison, WLBU2 showed MICs of 1.5–3.2  $\mu\text{M}$  against XDR *A. baumannii*, 2.9–4.7  $\mu\text{M}$  against XDR *K. pneumoniae*, and 9.3  $\mu\text{M}$  against *K. pneumoniae* KP2 strain.<sup>12</sup> These results are comparable to the study's findings.


Another study investigated the activity of two eCAPs; WLBU2 and WR12, along with colistin and LL37, against 142 clinical isolates. The clinical isolates were Gram-positive methicillin-resistant *S. aureus*, vancomycin-resistant enterococci, and Gram-negative *Enterobacteriaceae*, including *K. pneumoniae*, *Enterobacter aerogenes*, *E. cloacae*, *E. coli*, and *A. baumannii*. The mean MICs of eCAPs were  $\leq 10 \mu\text{M}$  against both Gram-negative and Gram-positive bacteria.<sup>22</sup>

Amoxicillin-clavulanate and ciprofloxacin were used for MIC testing against MDR *K. pneumoniae*. Tobramycin and imipenem were used for MIC testing against *A. baumannii*. The antimicrobial agents were chosen based on recommendations indicated in the


“Performance Standards for Antimicrobial Susceptibility Testing”, CLSI-2016, 26th edition. Most of the clinical isolates and ATCC strains were resistant to the antimicrobial agents.

The synergism test between WLBU2 and the four antimicrobial agents against planktonic bacteria was done by adding WLBU2 at its sub-inhibitory MIC for each respective isolate, with antimicrobial agents at different concentrations. Most clinical isolates selected for testing had MICs at the resistance cutoff values. Synergism was observed in several instances. Synergism between AMPs and antimicrobial agents has been described previously. A study from 2014 investigated the activity of four chimeric cationic peptides against 19 MDR *A. baumannii* isolates. The peptides showed MIC values between 3.125 and 12.5  $\mu\text{M}$  against all isolates. The isolates were resistant to all tested antimicrobial agents (ampicillin, cefotaxime,





**Figure 1** Viability of Vero cells and human skin fibroblasts exposed to WLBUE2. Vero cells or human skin fibroblasts were incubated with different concentrations of WLBUE2 or media alone (control) for 24 hrs. Cell viability was determined using the MTT assay. Experiments were run in triplicates. Bars represent means±standard error of the mean. WLBUE2 concentrations in µM correspond to 5.313, 10.625, 21.250, 42.500, 85, 170, 340, 680 µg/mL, respectively.




**Figure 2** Viability of Vero cells and skin fibroblasts exposed to WLBUE2 combined with antimicrobial agents. Vero cells or human skin fibroblasts were incubated with WLBUE2 at 12.500 µM (42.5 µg/mL) or 25 µM (85 µg/mL) combined with antimicrobial agents at the indicated concentrations for 24 hrs. Cell viability was determined using the MTT assay. Experiments were run in triplicates. Bars represent means±standard error of the mean.

ciprofloxacin, erythromycin, tobramycin, and polymyxin) except polymyxin. The four peptides showed synergy against one or two isolates when combined with cefotaxime, ciprofloxacin, or erythromycin.<sup>26</sup>

The ability of WLBUE2 to eradicate biofilms was investigated using the MBEC assay, the standard method to

evaluate agents' ability to eradicate bacterial biofilms. All *K. pneumoniae* and *A. baumannii* ATCC strains were subjected to the MBEC assay using WLBUE2 alone and in combination with antimicrobial agents. Representative clinical isolates in planktonic form that demonstrated synergism between WLBUE2 and antimicrobial agents



**Figure 3** Representative gel electrophoresis result for WLBU2 DNA binding assay. DNA binding assay was utilized to determine the ability of WLBU2 to bind bacterial plasmid DNA (pUC19 plasmid, 2686 base pairs); L: 1 KB DNA ladder (values are in base pairs); C: DNA alone (8.33 ng/ $\mu$ L); from 1 to 8 twofold diluted WLBU2 (200–1.563  $\mu$ M or 680–5.313  $\mu$ g/mL) combined with fixed DNA concentration (8.33 ng/ $\mu$ L); Electrophoresis was done at 140 V for 45 mins on 1% agarose; DNA was visualized under a UV transilluminator; no band shifts occurred for lanes 1–8 indicating no binding between WLBU2 and DNA.

were also utilized for MBEC testing. When tested alone, WLBU2 demonstrated high MBEC values. Hence, we investigated whether combining antimicrobial agents with WLBU2 at 25% MBEC would lead to biofilm eradication. Indeed, the combinations led to biofilm eradication in several instances.

Overall, an increase in WLBU2 MBEC levels was observed compared to planktonic MIC values against *K. pneumoniae* and *A. baumannii*. Similarly, two- to four-fold higher MBEC levels of WLBU2 were observed for the treatment of *P. aeruginosa* abiotic and biotic biofilms compared to the MIC values against planktonic cells.<sup>27</sup> Furthermore, it was reported by others that ciprofloxacin, erythromycin, and tobramycin alone were not able to reduce or inhibit biofilm formation by *A. baumannii*. However, when the agents were combined with chimeric cationic peptides, a reduction in biofilm formation was observed,<sup>26</sup> which is similar to what was observed for WLBU2.

A study has indicated that NK-18 (an eCAP) has the ability to not only associate with the bacterial plasma membrane, but also to internalize and target bacteria DNA. The study also reported that another membrane-active AMP, magainin 2, could not bind plasmid DNA even at 128  $\mu$ g/mL.<sup>4</sup> A study of two synthetic short peptides with potent activity against *S. aureus*, namely, RRIKA and RR, demonstrated that both peptides were able to bind plasmid DNA and delay its electrophoretic migration in agarose, especially at higher peptide concentrations.<sup>5</sup> The ability of WLBU2 to bind DNA as a potential mechanism for antimicrobial activity has not been previously investigated. WLBU2 at up to the tested

200  $\mu$ M (680  $\mu$ g/mL) level was not able to retard DNA mobility. Hence, WLBU2 mediates its activity via mechanisms other than binding of DNA.

MTT assay was used for measuring the viability of Vero cells and human skin fibroblasts. Vero cells (African green monkey kidney epithelial cells) were utilized to assess toxicity should WLBU2 alone or in combination with antimicrobial agents be used in vivo. Human skin fibroblasts were utilized to assess toxicity should WLBU2 alone or in combination with antimicrobial agents be used for topical applications on human skin. The International Organization for Standardization (ISO) guidelines for cytotoxicity testing (ISO 10993–5:2009) state that an agent is cytotoxic if cell viability falls below 70%.<sup>28,29</sup> WLBU2 effects on cell viability were tested at a wide range of concentrations. For both cell types, cell viability was reduced to  $\leq 12\%$  at high WLBU2 concentrations; 200–50  $\mu$ M or 680–170  $\mu$ g/mL. However, these concentrations corresponded with effective biofilm eradication, suggesting that WLBU2 will lead to considerable cell toxicity if used at MBEC values.

Vero cells and human skin fibroblasts viability percentages were  $>70\%$  at WLBU2 concentrations  $\leq 3.125$   $\mu$ M (10.625  $\mu$ g/mL) and  $\leq 12.500$   $\mu$ M (42.5  $\mu$ g/mL), respectively. Fortuitously, these values were similar to WLBU2's MIC values against planktonic cells. Hence, WLBU2 could be used at this range to eradicate planktonic cells without significant host cell toxicity.

Since cell viability was decreased at WLBU2 concentrations  $\geq 50$   $\mu$ M (170  $\mu$ g/mL), and since WLBU2 at sub-MBEC values (ie,  $<50$   $\mu$ M or 170  $\mu$ g/mL) demonstrated synergistic activity in eradicating biofilms of several isolates when combined with antimicrobial agents, we investigated the viability of Vero and human skin fibroblasts when treated with WLBU2 at 25 and 12.500  $\mu$ M (85 and 42.5  $\mu$ g/mL) combined with antimicrobial agents at different concentrations. Surprisingly, a significant decrease in cell viability was observed for all tested combinations. For comparison, a study of WLBU2's potential toxicity on J774 macrophages demonstrated reduced viability at 3–100  $\mu$ M for 1 hr, with 50% of the cells being lost at a concentration of 25  $\mu$ M.<sup>11</sup>

Despite the loss of cell viability when WLBU2 was combined with the antimicrobial agents, combination results showed excellent and substantial synergistic effect on some bacterial isolates and ATCC strains. This suggests that the combination could be useful for in vitro disinfection of planktonic bacteria and associated-biofilms, rather than in vivo application.

A study on eCAPs indicated that, WLBU2 had no cytotoxicity at concentration of  $\leq 20 \mu\text{M}$  for 6 hrs, using both hemolytic assay and MTT assay against peripheral blood mononuclear cells (PBMCs). The study also investigated antibacterial activity under acidic conditions for several eCAPs. WLBU2 displayed no significant difference in activity at acidic pH compared with neutral pH against *P. aeruginosa* and MRAS.<sup>12</sup> The viability results of WLBU2 against human skin fibroblasts in the current study are consistent with those reported on PBMCs, although in our protocol the exposure duration was 24 hrs instead of the 6 hrs used for PBMCs, which likely leads to an overestimation of potential toxicity.

The reasonably good selective toxicity of WLBU2 against bacteria coupled with low toxicity against eukaryotic cells may be explained by eCAPs' ability to form weak hydrophobic interactions with eukaryotic membranes due to the presence of cholesterol, and the formation of strong electrostatic interactions with the negatively charged bacterial membranes.<sup>30</sup>

## Conclusion

The MIC values of WLBU2 ranged from 12.500 to 3.125  $\mu\text{M}$  (42.5 to 10.625  $\mu\text{g/mL}$ ) against the clinical isolates and ATCC strains. High WLBU2 concentrations were needed to eradicate bacterial biofilms. However, at these concentrations, viability of Vero cells and human skin fibroblasts was reduced to  $<50\%$ . In contrast, at MIC values for planktonic cells, acceptable viability was observed ( $\geq 70\%$ ).

The combinations between WLBU2 sub-inhibitory concentrations and antimicrobial agents demonstrated synergism in several instances, suggesting the ability of using WLBU2 at lower MBEC levels to eradicate biofilms upon combination with antimicrobial agents. Nonetheless, eukaryotic cell toxicity of WLBU2 combined with antimicrobial agents was excessively high, potentially limiting future in vivo applications. Finally, WLBU2 did not demonstrate the ability to bind bacterial DNA.

Additional assays and cell types should be utilized to investigate potential cytotoxicity by WLBU2.

Based on the WLBU2's potent killing activity of MDR *A. baumannii* and *K. pneumoniae*, in vivo animal studies of WLBU2 pharmacokinetics and potential utility to treat bacterial infections, including those by intracellular bacteria might be useful. Similar investigations could be carried out for Gram-positive bacteria. The anti-bacterial mechanisms of WLBU2 alone and combined with antimicrobial agents should be elucidated, for instance, the

assessment of transmembrane pores formation by scanning electron microscopy, and effects on bacterial metabolism. The potential synergism between WLBU2 and other cationic-short AMPs is still unknown and could be the topic for future investigations. The observed high eukaryotic toxicity between WLBU2 and the antimicrobial agents even at low concentrations merit future investigations, especially as potential agents in the treatment of human tumors.

## Data availability

Raw data are available upon request from the corresponding author.

## Acknowledgments

This work was financially supported by the Deanship of Research of Jordan University of Science and Technology [Grant number 20170221].

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. World Health Organization. Implementation of the global action plan on antimicrobial resistance. *WHO GAPAMR NewsL*. 2017;2017(30):1–4
2. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol*. 2001;9(1):34–39.
3. Jefferson KK. What drives bacteria to produce a biofilm? *FEMS Microbiol Lett*. 2004;236(2):163–173. doi:10.1016/j.femsle.2004.06.005
4. Yan J, Wang K, Dang W, et al. Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin. *Antimicrob Agents Chemother*. 2013;57(1):220–228. doi:10.1128/AAC.01619-12
5. Mohamed MF, Hamed MI, Panitch A, Seleem MN. Targeting methicillin-resistant *Staphylococcus aureus* with short salt-resistant synthetic peptides. *Antimicrob Agents Chemother*. 2014;58(7):4113–4122. doi:10.1128/AAC.02578-14
6. Kalatzis PG, Castillo D, Katharios P, Middelboe M. Bacteriophage interactions with marine pathogenic vibrios: implications for phage therapy. *Antibiotics (Basel)*. 2018;7(1):15. doi:10.3390/antibiotics7030077
7. Sierra JM, Fuste E, Rabanal F, Vinuesa T, Vinas M. An overview of antimicrobial peptides and the latest advances in their development. *Expert Opin Biol Ther*. 2017;17(6):663–676. doi:10.1080/14712598.2017.1315402
8. Wang G. Human antimicrobial peptides and proteins. *Pharmaceuticals*. 2014;7(5):545–594. doi:10.3390/ph7050545
9. Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. *Biochim Biophys Acta*. 2016;1858(5):1044–1060. doi:10.1016/j.bbame.2015.10.013
10. Chu HL, Yip BS, Chen KH, et al. Novel antimicrobial peptides with high anticancer activity and selectivity. *PLoS One*. 2015;10(5):e0126390. doi:10.1371/journal.pone.0126390
11. Abdelbaqi S. *Novel Engineered Cationic Antimicrobial Peptides Have a Broad-spectrum Activity Against: Francisella Tularensis, Burkholderia Pseudomalli and Yersinia Pestis*. Pittsburgh: University of Pittsburgh; 2014.

12. Deslouches B, Steckbeck JD, Craig JK, Doi Y, Mietzner TA, Montelaro RC. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. *Antimicrob Agents Chemother*. 2013;57(6):2511–2521. doi:10.1128/AAC.02218-12
13. Deslouches B, Phadke SM, Lazarevic V, et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. *Antimicrob Agents Chemother*. 2005;49(1):316–322. doi:10.1128/AAC.49.1.316-322.2005
14. Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi J Biol Sci*. 2015;22(4):424–429. doi:10.1016/j.sjbs.2015.01.004
15. Bardbari AM, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental *Acinetobacter baumannii* isolates. *Microb Pathog*. 2017;108:122–128. doi:10.1016/j.micpath.2017.04.039
16. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev*. 1998;11(4):589–603.
17. O'Toole GA. Microtiter dish biofilm formation assay. *JoVE (journal of Visualized Experiments)*. 2011;30(47):e2437–e2437.
18. Lashua LP, Melvin JA, Deslouches B, Pilewski JM, Montelaro RC, Bomberger JM. Engineered cationic antimicrobial peptide (eCAP) prevents *Pseudomonas aeruginosa* biofilm growth on airway epithelial cells. *J Antimicrob Chemother*. 2016;71(8):2200–2207. doi:10.1093/jac/dkw143
19. Wikler MA, Alder J. *Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically*, M7. 11th ed. Pennsylvania: Clinical and Laboratory Standards Institute; 2009.
20. Yan H, Hancock RE. Synergistic interactions between mammalian antimicrobial defense peptides. *Antimicrob Agents Chemother*. 2001;45(5):1558–1560. doi:10.1128/AAC.45.5.1558-1560.2001
21. Yang K, Gitter B, Ruger R, et al. Antimicrobial peptide-modified liposomes for bacteria targeted delivery of temoporfin in photodynamic antimicrobial chemotherapy. *Photochem Photobiol Sci*. 2011;10(10):1593–1601. doi:10.1039/c1pp05100h
22. Deslouches B, Steckbeck JD, Craig JK, Doi Y, Burns JL, Montelaro RC. Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. *Antimicrob Agents Chemother*. 2015;59(2):1329–1333. doi:10.1128/AAC.03937-14
23. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M. Evaluation of different detection methods of biofilm formation in the clinical isolates. *Braz J Infect Dis*. 2011;15(4):305–311.
24. Knobloch JK, Horstkotte MA, Rohde H, Mack D. Evaluation of different detection methods of biofilm formation in *Staphylococcus aureus*. *Med Microbiol Immunol*. 2002;191(2):101–106. doi:10.1007/s00430-002-0124-3
25. Hancock RE, Falla T, Brown M. Cationic bactericidal peptides. In: *Advances in Microbial Physiology*. Vol. 37. Elsevier, New York; 1995:135–175.
26. Gopal R, Kim YG, Lee JH, et al. Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother*. 2014;58(3):1622–1629. doi:10.1128/AAC.02473-13
27. Deslouches B, Steckbeck JD, Craig JK, Doi Y, Burns JL, Montelaro RC. Engineered cationic antimicrobial peptides (eCAPs) to overcome multidrug resistance by ESKAPE pathogens. *Antimicrob Agents Chemother*. 2014;59(2):3914–3937. AAC.
28. Velasco-Ortega E, Jos A, Camean AM, Pato-Mourelo J, Segura-Egea JJ. In vitro evaluation of cytotoxicity and genotoxicity of a commercial titanium alloy for dental implantology. *Mutat Res*. 2010;702(1):17–23. doi:10.1016/j.mrgentox.2010.06.013
29. Haghi AK, Thomas S, Pourhashemi A, Hamrang A, Klodzinska E. *Nanomaterials and Nanotechnology for Composites: Design, Simulation and Applications*. CRC Press, Florida; 2015.
30. Biggin PC, Sansom MS. Interactions of alpha-helices with lipid bilayers: a review of simulation studies. *Biophys Chem*. 1999;76(3):161–183.

## Infection and Drug Resistance

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress